Engaging with social media platforms can provide real-time insights and diverse perspectives on the obesity medicines market. Here are some notable discussions:
Twitter (X):
- JAMA (@JAMA_current): Highlighted the rapid growth of GLP-1s in the compounding market due to supply shortages and expanding indications. Twitter
- Chamath Palihapitiya (@chamath): Commented on Amgen’s clinical trial data, noting the dominant positions of Eli Lilly and Novo Nordisk in the obesity drug market. Twitter
- Shares Magazine (@SHARESmag): Discussed the evolution of the obesity drug market, anticipating the introduction of daily oral tablets by 2026. Twitter
To stay informed about the latest developments in the obesity medicines market, consider the following sources:
- Ozmosi: Provides in-depth analyses of the GLP-1 agonists market, focusing on obesity treatments from leading pharmaceutical companies. Ozmosi
- IQVIA: Offers insights into market dynamics and projections, including discussions on the emergence of new markets for effective prescription medications targeting obesity. IQVIA
- Obesity Medicine Association: Features comprehensive guides on FDA-approved weight loss medications, including safety, dosage, and efficacy information. Obesity Medicine Association
- Health Advances: Analyzes the market access landscape for obesity drugs, providing expectations on payer views and coverage evolution over the next five years. Health Advances
- Fortune Business Insights: Publishes reports on the anti-obesity drugs market size and share, offering forecasts and growth trends. Fortune Business Insights

Market News
- Trump installs sweeping new tariffs, but pharma appears to dodge blowby Philip Neuffer (BioPharma Dive – Latest News) on April 2, 2025
The president will impose a baseline 10% tariff on all countries, as well as higher levies on certain nations. Pharmaceutical goods seems to be exempt, at least for now.
- Leqembi’s EU review drags on; Sanofi gets a new development headby BioPharma Dive staff (BioPharma Dive – Latest News) on April 2, 2025
The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of insolvency and Novartis hired a new top lawyer.
- UK life sciences venture capital funding lags behindby Akosua Mireku (Pharmaceutical Technology) on April 2, 2025
At the BioTrinity Conference, experts champion government funding programmes to bridge gap the in UK venture capital financing.
- US uncertainty weighs on IPO market while UK innovation could benefitby Jenna Philpott (Pharmaceutical Technology) on April 2, 2025
Panellists at the OBN BioTrinity 2025 conference in London discussed how US uncertainty is impacting the biopharma environment.
- FDA Grants Fast Track Designation to Biogen’s Novel Alzheimer Disease Drug Candidateby OncLive articles on April 2, 2025
BIIB080 marks the first antisense oligonucleotide targeting tau to enter clinical development for the treatment of Alzheimer disease.
- ACC 2025: GLP-1RAs may reduce incidence of AF/flutter and stroke in diabetic patientsby GlobalData Healthcare (Pharmaceutical Technology) on April 2, 2025
T2D has been associated with an increased risk of CV mortality and GLP-1RAs are being increasingly used as a T2D and obesity treatment.
- New genetic medicine CDMO acquires Landmark Bioby Kristin Jensen (BioPharma Dive – Latest News) on April 2, 2025
Artis BioSolutions joins a host of startups trying to improve development and manufacturing capacity for cutting-edge gene and cell therapies.
- ‘A cruel April Fool’s joke’: HHS layoffs characterized by confusion, errorsby Rebecca Pifer (BioPharma Dive – Latest News) on April 2, 2025
The sweeping workforce reduction that began Tuesday was made worse by mistakes and poor communication, including directions for some CMS employees to contact a director who died last year.
- FDA device office hit in HHS layoffsby Elise Reuter (BioPharma Dive – Latest News) on April 2, 2025
Teams working on device communications and policy were cut from the agency on Tuesday, according to multiple FDA workers.
- Organon acquires Actemra biosimilar’s US rights from Biogenby gullapalli (Pharmaceutical Technology) on April 2, 2025
Organon has announced the acquisition from Biogen of US regulatory and commercial rights for intravenous infusion of Tofidence.
- RFK Jr swings axe at US health agenciesby Ross Law (Pharmaceutical Technology) on April 2, 2025
Plans outlined by HHS Secretary Robert F Kennedy, Jr look set to target jobs at the US Department of Health & Human Services (HHS).
- AIRNA secures $155m to bring RNA-candidate to clinicby Jenna Philpott (Pharmaceutical Technology) on April 2, 2025
The Series B funds will support the launch of a Phase I/II clinical trial for AIR-001 to advance its RNA editing pipeline.
- Amneal and Shilpa introduce Boruzu in US for cancer treatmentby gullapalli (Pharmaceutical Technology) on April 2, 2025
Amneal Pharmaceuticals, along with Shilpa Medicare, has launched the new presentation of bortezomib, Boruzu.
- Analyzing the Theranos Appealsby OncLive articles on April 2, 2025
Matthew Yelovich, partner at Cleary Gottlieb, discusses the appeals of Elizabeth Holmes and Ramesh “Sunny” Balwani and the Ninth Circuit’s recent affirmation of their convictions.
- Pfizer and Flagship Pioneering Partner to Use AI-Powered Platform for New Drug Developmentby OncLive articles on April 2, 2025
Charles River Laboratories will work directly with the platform.
- Creating More Agile Systems for Future Public Health Emergenciesby OncLive articles on April 2, 2025
Marcel Botha, CEO of 10XBeta, discusses lessons from The Spiro Wave project that can be applied in creating more agile and responsive systems for future public health emergencies.
- Pharma Pulse 4/2/25: Financial Barrier to GLP-1s, The Future of Healthcare is Digital & moreby OncLive articles on April 2, 2025
The latest news for pharma industry insiders.
- Kanvas Bioscience’s New Research Shows Potential of HiPR-Map Platform for LBP Developmentby OncLive articles on April 2, 2025
The platform can reportedly outperform traditional methods.
- FDA accepts priority review of Apellis’ Empaveli sNDA for kidney diseasesby gullapalli (Pharmaceutical Technology) on April 2, 2025
Apellis Pharmaceuticals has announced US FDA acceptance of the sNDA and the granting of priority review status to Empaveli
- ACC 25: tirzepatide influences clinical trajectory of patients with HFpEF and obesityby GlobalData Healthcare (Pharmaceutical Technology) on April 1, 2025
GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.